Phase 1 Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- People who weigh at least 40 kilograms (about 88 pounds)
- People who agree to follow the contraceptive (birth control) requirements set out by the trial
- People who have a confirmed diagnosis of ulcerative colitis (UC), supported by clinical assessment, camera examination of the bowel, and tissue sample analysis
- People whose ulcerative colitis is confirmed as active by a camera examination of the bowel, with inflammation extending at least 15 centimetres from the end of the bowel
- People whose ulcerative colitis is considered moderately to severely active, based on a specific scoring system (called the modified Mayo score) with a result between 5 and 9, including a particular sub-score from the camera examination, as reviewed by a central team
Who may not be able to join:
- People who have a current diagnosis of Crohn's disease, fistulas (abnormal tunnels in or around the bowel or abdomen), abscesses, indeterminate colitis, unclassified inflammatory bowel disease, microscopic colitis, colitis caused by reduced blood flow, infection, or radiation, or active diverticular disease (small pouches causing problems in the bowel)
- People who have a stoma (an opening on the abdomen for waste) or a surgically created internal pouch (ileoanal pouch)
- People who currently have or are suspected of having a condition called primary sclerosing cholangitis (a disease affecting the bile ducts in the liver)
- People who do not have accessible veins suitable for blood draws or intravenous procedures
- People who have had a major surgery within 6 weeks before the screening visit, or who have a major surgery planned during the study period
- People who have had a history of alcohol, drug, or chemical misuse within the past year before screening
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 888-662-6728 (U.S. Only)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Area Under the Plasma Concentration-time Curve Up to Time t (AUC0-t [AUC last]) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine); Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUCinf) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine); Maximum Plasma Concentration (Cmax) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omep...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.